Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Women's Right To Choose Avastin Debated During House PDUFA Hearing

Executive Summary

Discussion of the status of Avastin's indication for metastatic breast cancer at a July 7 House hearing can be seen as a surrogate for several debates that could unfold during the user fee reauthorization process – including FDA approval standards, conflict-of-interest screening for advisory committees and pricing.
Advertisement

Related Content

Conflict-Of-Interest Policy Relaxation For FDA Cmtes. Could Be Easy PDUFA Add-on
Conflict-Of-Interest Policy Relaxation For FDA Cmtes. Could Be Easy PDUFA Add-on
Genentech Losing Its Legs? Avastin Study Proposal Undercut By Feasibility, Scientific Concerns
Not Another FDAAA – Observers Expect Fewer FDA Reforms In PDUFA V
Woodcock Defends Speed Of FDA Reviews, Cites 20 Approvals In First Half Of 2011
Avastin Down, But Not Out Yet In Metastatic Breast Cancer Indication
Avastin Down, But Not Out Yet In Metastatic Breast Cancer Indication

Topics

Advertisement
UsernamePublicRestriction

Register

PS053586

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel